957121-88-9Relevant articles and documents
Discovery of MK-3207: A highly potent, orally bioavailable CGRP receptor antagonist
Bell, Ian M.,Gallicchio, Steven N.,Wood, Michael R.,Quigley, Amy G.,Stump, Craig A.,Zartman, C. Blair,Fay, John F.,Li, Chi-Chung,Lynch, Joseph J.,Moore, Eric L.,Mosser, Scott D.,Prueksaritanont, Thomayant,Regan, Christopher P.,Roller, Shane,Salvatore, Christopher A.,Kane, Stefanie A.,Vacca, Joseph P.,Selnick, Harold G.
scheme or table, p. 24 - 29 (2010/11/04)
Incorporation of polar functionality into a series of highly potent calcitonin gene-related peptide (CGRP) receptor antagonists was explored in an effort to improve pharmacokinetics. This strategy identified piperazinone analogues that possessed improved
Substituted monocyclic CGRP receptor antagonists
-
Page/Page column 52-53, (2008/06/13)
Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.